newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

PRAX
  • Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced a proposed public offering of common stock and pre-funded warrants.
  • The company intends to grant underwriters a 30-day option to purchase up to 15% additional shares or pre-funded warrants at the public offering price less discounts.
  • Joint book-running managers include Piper Sandler, TD Cowen, Guggenheim Securities, & Truist Securities.
  • Lead managers are LifeSci Capital, Baird, & Oppenheimer & Co., while H.C. Wainwright & Co. & Needham & Company serve as co-managers.
  • The offering is conducted under a shelf registration statement on Form S-3ASR that became effective on December 23, 2024.
  • Final terms will be disclosed in a final prospectus supplement to be filed with the SEC.
  • The transaction is subject to market conditions & customary closing conditions, with no assurance regarding completion timing.